SCHEMBL3084837

SCHEMBL3084837

ClCc1cnc(SCc2ccccc2)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 4/20 0.41
MAPT P10636 2/20 0.41
CDK2 P24941 1/20 0.40
CDK1 P06493 1/20 0.40
CCNB1 P14635 1/20 0.40
FFAR1 O14842 1/20 0.40
MAPK1 P28482 1/20 0.40
PKM P14618 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CA1 P00915 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3082339 0.84 LMNA (0.47) LMNAHPGDHSD17B10ALDH1A1MAPT
SCHEMBL27174936 0.80 HSD17B10 (0.46) LMNAHPGDHSD17B10ALDH1A1MAPT
SCHEMBL27174954 0.78 LMNA (0.42) LMNAHPGDHSD17B10ALDH1A1MAPT
SCHEMBL1502786 0.77 HSD17B10 (0.46) LMNAHPGDHSD17B10ALDH1A1MAPT
SCHEMBL20954074 0.77 HDAC6 (0.39) LMNAHPGDALDH1A1SMN1; SMN2KMT2A
SCHEMBL3073391 0.75 ALDH1A1 (0.52) LMNAHPGDALDH1A1MAPTMAPK1
SCHEMBL27174924 0.75 FFAR1 (0.60) LMNAHPGDALDH1A1MAPTCDK2
SCHEMBL3087197 0.73 ALDH1A1 (0.50) LMNAHPGDHSD17B10ALDH1A1MAPT
SCHEMBL11751962 0.73 LMNA (0.56) LMNAHPGDHSD17B10ALDH1A1MAPT
SCHEMBL13143669 0.71 KMT2A (0.37) LMNAHPGDHSD17B10ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110092783-B Preparation method of thiamethoxam 湖南化工研究院有限公司 2020-11-20 CN disclosed
US-7795442-B2 Preparation of thiazoles SYNGENTA CROP PROTECTION, INC. (US) 2010-09-14 US disclosed
US-20090198054-A1 PREPARATION OF THIAZOLES SYNGENTA CROP PROTECTION, INC. (US) 2009-08-06 US disclosed
US-7538229-B2 Preparation of thiazoles SYNGENTA CROP PROTECTION, INC. (US) 2009-05-26 US disclosed
US-20080076920-A1 PREPARATION OF THIAZOLES SYNGENTA CROP PROTECTION, INC. (US) 2008-03-27 US disclosed
US-7323564-B2 Preparation of thiazoles SYNGENTA CROP PROTECTION, INC. (US) 2008-01-29 US disclosed
US-20070055063-A1 PREPARATION OF THIAZOLES SYNGENTA CROP PROTECTION, INC. (US) 2007-03-08 US disclosed
US-7161011-B2 Reactin a thiazole compound with glycidyl aldehyde SYNGENTA CROP PROTECTION, INC. (US) 2007-01-09 US disclosed
EP-0873326-B1 PROCESS FOR PREPARING 2-CHLOROTHIAZOLE COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2005-11-09 EP disclosed
EP-0946531-B1 PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2005-11-02 EP disclosed
US-6211381-B1 CHEMICAL INTERMEDIATES NOVARTIS CROP PROTECTION, INC. 2001-04-03 US disclosed
US-6121455-A CHLORINATION, SALT FORMATION NOVARTIS CROP PROTECTION, INC. (US) 2000-09-19 US disclosed
EP-0958286-A1 PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES Novartis AG (CH) 1999-11-24 EP disclosed
EP-0946531-A1 PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES Novartis AG (CH) 1999-10-06 EP disclosed
EP-0946532-A1 PREPARATION OF THIAZOLES Novartis AG (CH) 1999-10-06 EP disclosed
EP-0873326-A1 PROCESS FOR PREPARING 2-CHLOROTHIAZOLE COMPOUNDS Novartis AG (CH) 1998-10-28 EP disclosed
WO-1998032747-A1 PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES NOVARTIS AG (CH) 1998-07-30 WO disclosed
WO-1998027074-A1 PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES NOVARTIS AG (CH) 1998-06-25 WO disclosed
WO-1998027075-A1 PREPARATION OF THIAZOLES NOVARTIS AG (CH) 1998-06-25 WO disclosed
WO-1997020829-A1 PROCESS FOR PREPARING 2-CHLOROTHIAZOLE COMPOUNDS NOVARTIS AG (CH) 1997-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076920-A1 PREPARATION OF THIAZOLES OXSR1, OSR1, OSBPL3 LMNA 4017/4885HPGD 4868/4885HSD17B10 3139/4885
US-20070055063-A1 PREPARATION OF THIAZOLES SLC5A1, TST, TCOF1 LMNA 723/4885HPGD 4827/4885HSD17B10 2290/4885
US-20090198054-A1 PREPARATION OF THIAZOLES OXSR1, OSR1, OSBPL3 LMNA 4017/4885HPGD 4868/4885HSD17B10 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.